Replies to post #3034 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

"A typical royalty rate might be in the 6% range, which on sales of Paxlovid's magnitude, could be more than $1 billion annually in its peak years and may speak to why it might be worth Enanta's time and expenses to pursue this," he said in a report to clients.

Flo,

I believe the PFE forecast for Paxlovid in 2024 was about ~$8 billion. At 6% that would come to ~$500 million. That would be amazing for ENTA and ENTA shareholders but it remains a big IF.